UCLA Pathologist Dr. Richard Gatti Named to NeoStem Advisory Board

NEW YORK - NeoStem, Inc. (OTCBB:NEOI), the first company to specialize in the collection, processing and storage of stem cells from healthy adult donors for personal use in times of critical medical need, has announced that Richard Gatti, M.D., a professor at the University of California, Los Angeles (UCLA) and renowned Pathologist at the UCLA Medical Center, has joined the Company’s Advisory Board. Dr. Gatti was one of the early pioneers of bone marrow transplantation, among the earliest known forms of adult stem cell therapeutics, for immunodeficiency in the late sixties.

As a member of the Advisory Board, Dr. Gatti will help guide NeoStem’s programs as the Company moves to develop a nationwide health-industry network to capitalize on the predicted $8.5 billion stem cell therapeutics industry. Dr. Gatti’s academic and industry contacts are extensive both nationally and internationally and he is a strong proponent of adult stem cell therapies.

“Dr. Gatti’s distinguished work at UCLA will provide key validation as we move to expand our services in Los Angeles and in the west coast region,” said Robin Smith, M.D., Chief Executive Officer of NeoStem. “We are very pleased to welcome him as a strong addition to our Advisory Board. We look forward to his guidance and perspective that only leading scientists and physicians like Dr. Gatti can provide.”

Dr. Gatti is also a leading authority in the field of gene therapeutics and has authored or co-authored hundreds of papers related to the molecular identification and treatment of genetic disorders. He has worked for many years to help find a cure for Ataxia-Telangiectasia, a progressive neurological disorder of childhood, associated with increased cancer risk, immunodeficiency, radiosensitivity, and cell cycle defects.

“I believe that NeoStem’s pioneering stem cell-based services are lighting the way to what may very well become the next great revolution in medicine,” said Dr. Gatti. “I look forward to working with the other distinguished members of the Company’s Advisory Board to provide the guidance they need to realize their forward-thinking vision.”

NeoStem’s visionary senior management, non-capital intensive business model and proprietary processes are making an immediate impact in what many believe to be the “next big thing in consumer health marketing.” The Company has termed this paradigm shift in the medical industry as “bio-insurance,” which empowers health-conscious adults to have their own (autologous) stem cells collected and banked to ensure prompt access for therapeutic use in times of critical medical need.